Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Laparoscopic Ultrasound-Guided Removal of Multiple Uterine Fibroids

19 novembre 2026 mis à jour par: Hua Li

Laparoscopic Ultrasound-Guided Laparoscopic Myomectomy for Multiple Uterine Fibroids: A Prospective Randomized Controlled Trial

This study will examine whether ultrasound guidance during laparoscopic surgery can help surgeons remove uterine fibroids more completely. Uterine fibroids are noncancerous growths in the womb (uterus). Small fibroids or those deep in the uterine wall may be difficult to identify during surgery. Laparoscopic ultrasound uses a probe inside the abdomen to provide images of the uterus during the operation.

The study plans to enroll 110 premenopausal women aged 20 to 50 who have multiple uterine fibroids, need surgery, and wish to keep their uterus. Participants will be assigned by chance to laparoscopic ultrasound-guided myomectomy or conventional laparoscopic myomectomy, with 55 participants planned for each group. Myomectomy is surgery to remove fibroids while preserving the uterus.

The main outcome is the percentage of fibroids removed. For each participant, this is calculated by dividing the number of fibroids removed during surgery by the total number removed plus the number remaining on postoperative imaging, and multiplying by 100. Remaining fibroids will be assessed by transvaginal ultrasound or pelvic magnetic resonance imaging within 3 months after surgery.

Researchers will also assess the percentage of participants with remaining fibroids at 3 months, the difference between the number of fibroids removed and the number identified before surgery, surgical safety, postoperative recovery, and questionnaire scores related to sexual function, disability, anxiety, and quality of recovery. Follow-up visits are scheduled at 1, 3, and 12 months after surgery.

Aperçu de l'étude

Description détaillée

Preoperative magnetic resonance imaging will be used to assess and count uterine fibroids. During laparoscopic ultrasound-guided myomectomy, the ultrasound probe will be placed in direct contact with the uterus to help locate fibroids and guide their removal. This approach is intended to improve identification of small or deep fibroids that may not be apparent on visual inspection. In both study groups, decisions about fibroid removal will be individualized, with clinical benefit and safety as the priorities.

Allocation will use stratified block randomization based on age, fibroid number, and maximum fibroid diameter, with a block size of four. A statistician who is not involved in recruitment or clinical intervention will generate the randomization sequence. Group assignments will be kept in sequentially numbered, sealed, opaque envelopes and revealed after completion of the baseline assessment and confirmation of enrollment.

Surgeons will be aware of treatment allocation. Outcome assessors and data analysts will remain blinded to group assignment.

Type d'étude

Interventionnel

Inscription (Estimé)

110

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine, 100024
        • Beijing Chao Yang Hospital, Capital Medical University
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

20 ans à 50 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • Symptomatic multiple uterine fibroids causing symptoms such as abnormal uterine bleeding, anemia, or pressure symptoms, with an indication for laparoscopic myomectomy and a desire to preserve the uterus.
  • Diagnosis established through clinical evaluation, preoperative transvaginal ultrasound, and magnetic resonance imaging (MRI), with MRI used for the final assessment and fibroid count.
  • Age 20 to 50 years and premenopausal, with or without future fertility plans.
  • No contraindications to laparoscopic surgery.

Exclusion Criteria:

  • Concomitant submucosal fibroids classified as FIGO types 0-2.
  • Findings suspicious for malignancy on preoperative assessment.
  • Uterine size equivalent to 20 weeks of gestation or greater; a history of pelvic inflammatory disease; severe endometriosis; grade III or IV uterine prolapse; or a history of intestinal obstruction, recurrent pelvic inflammatory disease, pelvic tuberculosis, or surgery for pelvic or abdominal tumors.
  • Known severe hepatic or renal dysfunction.
  • Known hematological disorders, bleeding or coagulation disorders, active bleeding at any site, or a bleeding tendency.
  • Severe central nervous system, cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine or metabolic, musculoskeletal, or psychiatric disorders. Endocrine or metabolic disorders include thyroid disease, Cushing's syndrome, and hyperprolactinemia.
  • Acute infection.
  • Inability to sign the informed consent form.
  • Known or suspected poor adherence that would prevent completion of the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Laparoscopic Ultrasound-Guided Myomectomy

Participants will undergo laparoscopic myomectomy with intraoperative laparoscopic ultrasound guidance to locate uterine fibroids and assist their removal.

During laparoscopic myomectomy, a laparoscopic ultrasound probe will be placed in direct contact with the uterus to identify and localize fibroids and guide their removal. Fibroid removal will be individualized according to clinical benefit and safety.

Comparateur actif: Conventional Laparoscopic Myomectomy

Participants will undergo conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance.

Uterine fibroids will be removed using conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance. Fibroid removal will be individualized according to clinical benefit and safety.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Fibroid Removal Rate
Délai: During surgery and within 3 months after surgery

For each participant, the fibroid removal rate is calculated as the number of fibroids removed during surgery divided by the sum of the number removed during surgery and the number of residual fibroids detected by postoperative transvaginal ultrasonography or pelvic magnetic resonance imaging, multiplied by 100.

During surgery and within 3 months after surgery

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Operative Time
Délai: During surgery

Duration of the surgical procedure, measured in minutes.

During surgery
Residual Uterine Fibroid Rate
Délai: 3 months after surgery (+/- 14 days)

Percentage of participants with at least one residual uterine fibroid detected by transvaginal ultrasonography or pelvic magnetic resonance imaging at the 3-month postoperative visit. The rate is calculated as the number of participants with residual fibroids divided by the total number who underwent surgery in each group, multiplied by 100.

3 months after surgery (+/- 14 days)
Difference Between Removed and Preoperatively Identified Fibroid Counts
Délai: Preoperative assessment and during surgery

For each participant, the difference is calculated as the number of fibroids removed during surgery minus the number identified on preoperative magnetic resonance imaging.

Preoperative assessment and during surgery
Estimated Intraoperative Blood Loss
Délai: During surgery

Estimated volume of blood lost during surgery, measured in milliliters.

During surgery
Participants With Intraoperative Complications
Délai: During surgery

Number of participants experiencing at least one intraoperative complication, including hematoma, ureteral injury, or neurovascular injury.

During surgery
Participants With Postoperative Complications
Délai: From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)

Number of participants experiencing at least one postoperative complication, assessed during postoperative hospitalization and at scheduled follow-up visits.

From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)
Postoperative Length of Hospital Stay
Délai: Perioperative

Time from completion of surgery to hospital discharge, measured in days.

Perioperative
Postoperative Pain Score
Délai: 2 and 6 hours after surgery

Postoperative pain intensity assessed using a visual analog scale at 2 and 6 hours after surgery. Higher scores indicate more severe pain.

2 and 6 hours after surgery
Time to First Postoperative Ambulation
Délai: Perioperative

Time from completion of surgery to first postoperative ambulation, measured in hours.

Perioperative
Time to First Postoperative Flatus
Délai: Perioperative

Time from completion of surgery to first passage of flatus, measured in hours.

Perioperative
Duration of Postoperative Uterotonic Treatment
Délai: Perioperative

Duration of postoperative uterotonic medication use, measured in hours.

Perioperative
Time to Postoperative Drain Removal
Délai: Perioperative

Time from completion of surgery to removal of the surgical drain, measured in hours, among participants with a drain placed.

Perioperative
Participants With Postoperative Urinary Dysfunction
Délai: 1, 3, and 12 months after surgery (each visit window: +/- 14 days)

Number of participants with postoperative urinary dysfunction, assessed at each scheduled follow-up visit.

1, 3, and 12 months after surgery (each visit window: +/- 14 days)
Participants With Postoperative Bowel Dysfunction
Délai: 1, 3, and 12 months after surgery (each visit window: +/- 14 days)

Number of participants with postoperative bowel dysfunction, assessed at each scheduled follow-up visit.

1, 3, and 12 months after surgery (each visit window: +/- 14 days)
Change From Baseline in Female Sexual Function Index Score
Délai: Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)

Change from the preoperative baseline in the total Female Sexual Function Index score at each postoperative assessment. The questionnaire assesses sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate better sexual function.

Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)
Change From Baseline in Oswestry Disability Index Score
Délai: Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)

Change from the preoperative baseline in the Oswestry Disability Index score at each postoperative assessment. The questionnaire assesses disability associated with lower back or leg pain. Higher scores indicate greater disability.

Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)
Change From Baseline in Zung Self-Rating Anxiety Scale Score
Délai: Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)

Change from the preoperative baseline in the Zung Self-Rating Anxiety Scale score at each postoperative assessment. The questionnaire contains 20 items assessing anxiety symptoms. Higher scores indicate more severe anxiety.

Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
15-Item Quality of Recovery Questionnaire Score
Délai: Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)

Total score on the 2025 Chinese version of the 15-item Quality of Recovery questionnaire at each postoperative assessment. Total scores range from 0 to 150, with higher scores indicating better quality of recovery. Changes between postoperative assessments will be evaluated.

Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 janvier 2029

Achèvement de l'étude (Estimé)

1 décembre 2029

Dates d'inscription aux études

Première soumission

28 octobre 2026

Première soumission répondant aux critères de contrôle qualité

19 novembre 2026

Première publication (Réel)

20 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

19 novembre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

There is no plan to share de-identified individual participant data with researchers outside the study team.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner